Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
To pay the taxes that are due next year if you expect many more shares. They set aside about 250 million shares for themselves that have not been doled out yet. I would like to give a big raspberry to those voting for that undeserved set aside last ASM.
My understanding it would be based on the market price if given for free. It may be different for options that may include the exercise price.
You KNOW. Sorry. Missed a word.
You I dislike this management team and clearly not a fan of the BOD. But, I do not read it your way. I expect them to grant themselves large bonuses by year end that they will be required to pay taxes on next year.
You may be correct but I do not see it that way. They would all be selling in your scenario if it was that obvious.
“Advent received development grants from the U.K. based on its independence from NWBO. “
Mendacious. No proof of that. The only advantage I have seen was when revenue goals were not to be met by the development agreement NWBO could give a contract to Advent to claim revenue.
The reason Singapore does well in healthcare. Personal responsibility. Mandatory health savings accounts. You spend less when more of it comes out of your pocket.
“In Singapore, health care is financed both publicly and privately. About 41% of total health care costs are covered by the government, which funds much of the cost of hospitalizations and exercises tight control over hospital prices to limit spending. People use individual health savings accounts, known as Medisave, to pay for nonhospital care. Medisave accounts are mandated by the government, funded by salary deductions, and controlled by the individual. To enable individual choice in how to spend health care dollars, the Ministry of Health publishes health service prices.”
It is mind blowing and why this has not jumped to the submission stage with the FDA is beyond comprehension. I would sure like an explanation even if we are not directly involved in the trial. Because NWBO will reap all commercial benefits from the vaccine.
On my second thought about your post - If management cannot stand the scrutiny when transparent by message board posters, then we really are in trouble. Time for this company to grow up!
Cost plus 15% was for the work performed to set up the facility. Still no word on commercial product cost or revenue we can expect.
We all know these past numbers. You need forward looking estimates if you want any decent analyst following the company. This management team is delinquent.
Have zero clue how you imply anything from that number. It has to do with daily trading by market makers.
You are a shareholder. Owner of the company. Not knowing what Advent will be paid for producing commercial product has impact on any investment decision with this company.
You own and helped pay for the buildout of a manufacturing facility and for work performed by Advent. Not knowing a return is willful blindness. At this point management should be providing targets for revenue for the company. Pessimistic and optimistic. Long past due for any investor. There is a reason only the creepiest of analysts (if you want to call him an analyst) follow the company. Quarterly calls and well thought out targets bring accredited analysts.
The reason some people you want to keep in the dark are here posting because the company keeps shareholders in the dark. Easy to make a negative narrative with an information vacuum.
If I went along with your wishful thinking it should only be to shareholders of record at each occurrence of spoofing. But I think that is more than fantasy.
We have waited a great deal of time and still no answers from management. I think as a shareholder I am entitled to these facts. Need quarterly conference calls so a proper analyst can ask a real time question with follow up. Instead we get the Big Biz Show. Sad.
Anything I know about wild swings indicates an event. Good or bad.
Not for me. I want a decent shot at real success. Change the management with experienced capable people who have demonstrated an ability to perform. If that still doesn’t work, I will shorten my horizon.
What you see is a total of 1.7 B authorized shares that will more than likely all be put into circulation by the time management gives themselves their bonuses over the next couple of years. The current C shares are converted to common following a three month waiting period. So those shares are being purchased to fund the company with some investors. When they are converted, they show up in the number. The other conversions are warrants that also put shares in circulation. Having angst or concern or a question about what you see is not worth the time. When they finally start making real money the total outstanding shares will be 1.7 Billion. The company did it to themselves and to shareholders. Just a fact.
True about $100B. No argument. But the present team has destroyed value over their tenure. I have witnessed over a decade of excuses. Hold back bonuses and hold them accountable.
An indication of expectations provided by management. To think so many years after Data Lock the paperwork is still not submitted to only ONE of the four RAs. The last excuse was the printers hired. Prior to that all the pages to be scanned. You cannot make it up. Dismiss the top two clowns steering the clown car. The May 10 debacle was my tipping point. Now I can add Oct. Friday the 13th to the list. Two months beyond that milestone now.
Never met a schedule given or implied in over a decade. People need to be held accountable.
You have to scratch your head in bewilderment that these folks are still in charge. Two months late now for a task that should have been finished within a year following TLD. Be thankful spoofing is run by program trading. The capacity of management to execute properly throws shade on their claims.
Just wait for the bonuses prior to the ASM that will occur when? How I miss the prior to COVID announcement that we would have something really significant to hear at that ASM. I am still waiting to be dazzled.
He was not implying what you suggested. Just a fact. He nor I doubt what the investment could be worth.
He didn’t imply any such notion. I am firmly in his camp about missed promises and for me mismanagement. Doesn’t imply I will sell prior to an expected event. History with this management team has proven expected events do not occur when you have been conditioned to expect them. The last Oct. Friday the 13th showed a 45 day outlook was incapable of the management team meeting. And we are 2 months past that point. Incompetence.
Probably because shareholders and the market in general has no idea what the company is about and what they are slated to do over the next year. If management cannot explain this - no one can.
Navid just sold shares for tax purposes. Probably expects a big bonus that he will now have the funds to pay taxes on.
“What if the company is just fighting extremely evil and greedy forces”
Shareholders
The big lie or incompetent to state.
Bold prediction.
Maybe not an ASM by year’s end but I bet bonuses are given prior to year’s end. Malik purchased shares and immediately sold for tax purposes. Bet he wants it for taxes on a bonus issued by the end of year.
So they all get bonuses by Dec 31st and the ASM happens shortly after.
May be true. But we were told almost a year ago partnerships would be struck. Even if only in trials to come may have been implied.
“This is just an observation, but I would imagine the UK submission is being assembled in a way that they can use it for other regulatory bodies as well with minimal tweaking. “
They pretty much implied this after the first 45 day period missed on Oct 13. Begs the question - How come they didn’t consider this 12 months ago. Must be just my foolish point of view of how a company should operate. Always excuses. Last ASM they were scanning over a million pages. If they digitized everything while the data was taken, that nightmare could have been avoided. Next it is the printers. Pick a proper subcontractor to print, you would have avoided the latest excuse.
Very tired of their excuses. Time for new leadership.
Fortunately for you as a new shareholder that you did not experience the last decade of failure to meet any promised time estimates. If they imply the timeframe of soon, expect a year to three years. The past August 45 day schedule will end up more than 90 days. Good product, c(@p managers. Best to hope the top two souls at the top are replaced.
The management team just makes me sick. Never any accountability. They deserve zero bonus. Bunch of dopes. Put in capable executives and the stock would triple or more.
Such f$$& - ups.
“ I believe the publisher was acquired by a bigger publisher, and the bigger publisher found problems with the application, and together with LP and crew, worked to significantly improve the application. “
If this is true, whose fault is it for selecting a sub par publisher in the first place? MANAGEMENT!
Why cut these folks any slack a minute more? Find competent biotech executives in immunotherapy. If this wasn’t obvious on the May 10 debacle it sure is now.
You have been a shareholder for a long time. Me - over a decade. After years of stumbling I finally had to call it out after the May 10 massacre. The top 2 souls need replacement by competent biotech executive.
I would even agree to give them shares if they left.
A clown show. The arguments for and against authorizing their bonus landslide pre ASM are moot. Everyone should know how to vote if taken today.
The was an analyst paper out about a year ago stating expected approval for Australia in late 2024. Granted scheduling slides to the right on the chart but I would expect FDA prior to Australia.
Not a great strategy but here’s to hoping.
They would be doing it today if people could afford the vaccine. In mid 2024 it should be available in the UK but if you have US insurance Americans will be in the same position as they are today. It will finally become a reality for the UK patients. Not until FDA approval will US patients have a chance to get the vaccine and based on Ashkan’s talk it looks like the US rates last on the submission schedule out of the 4 RAs.
I didn’t forget. The rest of my post provided the caveat.
Doubt that. The remaining C shares are probably for management. The conversations of Cs that people hold and this last loan I would “hope” brings them into a substantial revenue period.
But as someone who has been here over a decade does make me question any promise or outlook. As stated we were expecting trial partnerships almost a year ago. I am not saying it will not happen but expectations based on what little we have been offered more than likely becomes years in time.
There are only a few die hard fans of management left on this message board that have been here before data lock.
At least it looks to not include convertible shares.
Could be a step up into production.